GE Capital provides capital to XDx to help increase commercialization of AlloMap molecular diagnostic test

GE Capital, Healthcare Financial Services announced today that it has provided, as sole lender, a $12.5 million senior secured multi-draw term loan facility to XDx, Inc. ("XDx"). The financing provides XDx with working capital to expand the commercialization of its FDA-cleared, innovative, noninvasive AlloMap® molecular diagnostic test and pursue the development of other gene expression-based tests for autoimmune diseases including lupus.

“We are pleased to provide capital to XDx to help them expand the commercialization of the FDA-cleared AlloMap® molecular diagnostic test”

XDx is a San Francisco Bay Area-based molecular diagnostics company focusing on non-invasive gene expression-based tests for the monitoring of organ transplant rejection and autoimmune diseases.

"GE Capital, Healthcare Financial Services has been a supportive financing resource, creating a deal structure specific to our long-term commercialization strategy," said Jean-Frederic Viret, PhD, XDx's chief financial officer.

"We are pleased to provide capital to XDx to help them expand the commercialization of the FDA-cleared AlloMap® molecular diagnostic test," said Anthony Storino, senior managing director, GE Capital, Healthcare Financial Services, Life Sciences. "Our combination of healthcare and financial expertise enabled us to provide XDx with the best financing solution to meet their overall business objectives."